Shaji K Kumar MD

Hematologic Oncology

Consultant at Mayo Clinic

200 1st St SWRochester, MN 55905
Phone+1 507-284-2511

Dr. Kumar is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kumar's full profile Already have an account?

Summary

Shaji K. Kumar, MD, is a Consultant in the Division of Hematology and the Mark and Judy Mullins Professor of Hematological Malignancies at the Mayo Clinic in Rochester, Minnesota. He serves as Research Chair for the Division of Hematology. Dr. Kumar received his medical degree from the All India Institute of Medical Sciences, New Delhi, India. His postdoctoral training included a residency in Internal Medicine at the same institute, followed by a residency in Internal Medicine and a fellowship in hematology/oncology at the Mayo Clinic Graduate School of Medicine in Rochester, Minnesota. He then completed a Mayo Foundation Fellowship at the Dana-Farber Cancer Institute in Boston. Dr. Kumar’s research centers on developing new drugs and drug combinations for treating myeloma. He is the Principal Investigator of multiple phase 1, 2, and 3 clinical trials. Additionally, he studies the mechanisms behind disease progression from precursor conditions and risk stratification of plasma cell disorders. His laboratory aims to understand the role of the bone marrow microenvironment in the development and progression of myeloma. Dr. Kumar serves as Chair of the NCCN Multiple Myeloma Guidelines Panel. He is the President of the International Society of Amyloidosis and the Vice President of the International Myeloma Society. He is the current Editor in Chief of The Hematologist, the American Society of Hematology’s official member newsletter.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1999 - 2003
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1997 - 1999
Institute Rotary Cancer Hospital, All-India Institute of Medical SciencesSenior Resident, 1996 - 1997
All India Institute of Medical SciencesClass of 1993
All-India Institute of Medical SciencesInternship, 1992

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MN State Medical License 1999 - 2027
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2017
CMS Meaningful Use Stage 2 Certification Mayo Clinic Patient Lists, Mayo Clinic, 2014-2017
CMS Meaningful Use Stage 2 Certification Mayo Clinic Electronic Notes, Mayo Clinic, 2014-2017

Clinical Trials

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
COMPLETED
PHASE1
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Start of enrollment: 2007 Aug 29
COMPLETED
PHASE1, PHASE2
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
COMPLETED
PHASE2

Publications & Presentations

PubMed

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.
Kenneth J C Lim, Shaji Kumar, Ricardo Parrondo, Saurabh Chhabra, Melinda Tan
American Journal of Hematology. 2026-09-01
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.
Daniel G Packard, Shaji K Kumar, Angela Dispenzieri, Prashant Kapoor, Guneet Janda
American Journal of Hematology. 2026-09-01
Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma.
Mahin Bhatt, S Vincent Rajkumar, Shaji Kumar
European Journal of Haematology. 2026-08-25

Journal Articles

Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma
S Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation
Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse
Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature

Books/Book Chapters

Clinical malignant hematology.
Chapter: Monoclonal gammopathy of undetermined significance
Page 943 - 954Kumar S, Greipp PREditors: Sekeres MA, Kalaycio ME, Bolwell BJ.McGraw-Hill Medical, New York
Myeloma therapy: pursuing the plasma cell.
Chapter: Lenalidomide for initial therapy of newly diagnosed multiple myeloma
Page 279 - 288Kumar SEditors: Lonial S.Humana, Totowa
Antiangiogenic cancer therapy.
Chapter: Pathophysiologic role of VEGF in hematologic malignancies
Page 91 - 129Podar K, Kumar S, Chauhan D, Anderson KCEditors: Davis DW, Herbst RS, Abbruzzese JL.CRC Press, Boca Raton

Abstracts/Posters

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Approaches To Achieve the Best Possible Outcomes in Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Dual Antigen Targeting of Drug-Resistant Extramedullary MyelomaJanuary 22nd, 2026
Talquetamab, Teclistamab Combo Yields Deep, Durable Responses for RRMM with EMDJune 26th, 2025
$Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma$
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple MyelomaJune 19th, 2025

Grant Support

Impact of Genetic susceptibility along the continuum from MGUS to MMMAYO CLINIC ROCHESTER2022–2027
Onset and biomarkers for progression of monoclonal gammopathiesMAYO CLINIC ROCHESTER2012–2025